Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 76 AL 90

Effects of Exercise on Functional Performance and Fall Rate in Subjects with Mild or Advanced Alzheimer's Disease: Secondary Analyses of a Randomized Controlled Study

Öhman H, Savikko N, Strandberg T, Kautiainen H, Raivio M, Laakkonen ML, Tilvis R, Pitkälä KH.

Dement Geriatr Cogn Disord. 2016;41(3-4):233-41. doi: 10.1159/000445712. Epub 2016 May 10.

MicroRNAs as Therapeutic Targets for Alzheimer's Disease

Di Meco A, Praticò D.

J Alzheimers Dis. 2016 May 7;53(2):367-72. doi: 10.3233/JAD-160203.

Amyloid beta directed antibody for Alzheimer's disease, an evidence based meta-analysis

Li C, Ma Q, Chen S, Feng J, He Y.

Cell Mol Biol (Noisy-le-grand). 2016 Apr 30;62(4):83-7.

Targeting New Pharmacological Approaches for Alzheimer's Disease: Potential for Statins and Phosphodiesterase Inhibitors

Sallustio F, Studer V.

CNS Neurol Disord Drug Targets. 2016;15(6):647-59. doi: 10.2174/1871527315666160518123727.

Insulin and the Future Treatment of Alzheimer's Disease

Semprini R, Koch G, Belli L, Lorenzo FD, Ragonese M, Manenti G, Sorice GP, Martorana A.

CNS Neurol Disord Drug Targets. 2016;15(6):660-4. doi: 10.2174/1871527315666160518123049.

Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer's Disease

Giubilei F.

CNS Neurol Disord Drug Targets. 2016;15(6):683-9. doi: 10.2174/1871527315666160518122917.

A comparative evaluation of treatments with 17β-estradiol and its brain-selective prodrug in a double-transgenic mouse model of Alzheimer's disease

Tschiffely AE, Schuh RA, Prokai-Tatrai K, Prokai L, Ottinger MA.

Horm Behav. 2016 Jul;83:39-44. doi: 10.1016/j.yhbeh.2016.05.009. Epub 2016 May 19.

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy

Sengupta U, Nilson AN, Kayed R.

EBioMedicine. 2016 Apr;6:42-49. doi: 10.1016/j.ebiom.2016.03.035. Epub 2016 Apr 5.

The news advances on Alzheimer's disease's therapeutics

Sun HQ, Zhang X, Huang WJ, Chen WW.

Eur Rev Med Pharmacol Sci. 2016 May;20(9):1903-10.

Aβ immunotherapy for Alzheimer's disease: where are we?

Güell-Bosch J, Montoliu-Gaya L, Esquerda-Canals G, Villegas S.

Neurodegener Dis Manag. 2016 Jun;6(3):179-81. doi: 10.2217/nmt-2016-0006. Epub 2016 May 27.

[Internal consistency and construct validity of the Quality of Life in Alzheimer's Disease (QoL-AD) proxy – a secondary data analysis]

Hylla J, Schwab CG, Isfort M, Halek M, Dichter MN.

Pflege. 2016 Jul;29(4):183-91. doi: 10.1024/1012-5302/a000494. Epub 2016 May 30.

Caloric restriction: beneficial effects on brain aging and Alzheimer's disease

Van Cauwenberghe C, Vandendriessche C, Libert C, Vandenbroucke RE.

Mamm Genome. 2016 Aug;27(7-8):300-19. doi: 10.1007/s00335-016-9647-6. Epub 2016 May 30.

[Disruption of iron homeostasis and relevant pharmacotherapies in Alzheimer’s disease]

Zhao XY, Wang Y, Wang GB, Zhang JJ.

Yao Xue Xue Bao. 2016 Jun;51(6):866-72.

Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia

Owen RT.

Drugs Today (Barc). 2016 Apr;52(4):239-48. doi: 10.1358/dot.2016.52.4.2479357.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias